Skip To Main Content
Jin-Ji Yang on Muck Rack

Jin-Ji Yang

As seen in: The Lancet, OncLive, European Journal of Cancer, Lung Cancer, Cancer Treatment Reviews, TechTrends
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jin-Ji

Contact Jin-Ji, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer

|
By Jin Ho Kang, Weineng Feng, Zi-Hao Chen, Jun-Wei Su, Hua-Jun Chen, Wen-xian Wang, Shirong Zhang, Qian Wang, Zexin Chen, Wen-Zhao Zhong, Chun-wei Xu, Jin-Ji Yang, Qiu-Mei Deng
| Lung Cancer Verified
Open in Who Shared Issue with article?

Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments

|
By Mei-Mei Zheng, Hai-Yan Tu, Jin-Ji Yang, Xu-chao Zhang
| European Journal of Cancer Verified
Highlights • Selected NSCLC patients with leptomeningeal metastases might benefit from ICIs. • ECOG-PS score is related with outcome of ICIs in leptomeningeal metastases. • Our study support ICIs as one of the options for some leptomeningeal metastases. Abstract Objective Leptomeningeal metastases (LM) occur in up to 5% of non–small cell lung cancer (NSCLC) patients and often develop after previous systemic treatments.
Open in Who Shared Issue with article?

A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002)

|
By Zhen Wang, Guangdong Academy, Cheng Huang, Jin-Ji Yang
| European Journal of Cancer Verified
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig. 1 Trial design. Chemotherapy for patients with NSCLC consisted of carboplatin (area under the concentration–time curve [AUC], 5), every 3 weeks for up to six cycles plus nab-paclitaxel (135 mg per square meter) on day1 and 8 each cycle or gemcitabine (1250 mg per square meter) on day 1 and 8 each cycle. NSCLC, non–small cell lung cancer. Fig.
Open in Who Shared Issue with article?
See all 9 licensed articles (10 Total)